Breaking
Markets
EUR/USD1.1603 0.07%GBP/USD1.3429 0.09%USD/JPY159.13 0.01%USD/CHF0.7856 0.11%AUD/USD0.7130 0.12%USD/CAD1.3807 0.04%USD/CNY6.8079 0.19%USD/INR95.88 0.19%USD/BRL5.0118 0.09%USD/ZAR16.47 0.05%USD/TRY45.71 0.00%Gold$4,510.50BTC$75,468 1.62%ETH$2,058 2.76%SOL$84.07 3.15%
South America

Radiopharma maker Lantheus weighs potential $7 billion sale after Curium offer

Bloomberg reports that US radiopharmaceutical maker Lantheus Holdings is weighing a preliminary buyout offer worth approximately USD 7 billion from rival Curium. The company is also in talks with other potential bidders. Lantheus shares jumped 12.8 percent in after-hours trading on the report.

Exterior of a modern pharmaceutical laboratory building in daylight
Photo: Pixabay / Pexels
Investing.com Americas2 h agoLNTH

Bloomberg reports, citing people familiar with the matter, that New Jersey-based radiopharmaceutical maker Lantheus Holdings is weighing a preliminary cash offer of approximately USD 7 billion from Curium Pharma, owned by French private equity firm CapVest. The process is at an early stage and Lantheus's board has retained Goldman Sachs and JPMorgan as advisers to oversee any sale process.

Lantheus is the market leader in prostate cancer imaging through its Pylarify PSMA-targeted PET agent and the DEFINITY ultrasound contrast agent; its fiscal 2025 revenue reached USD 1.52 billion. CEO Brian Markison said at an internal investor meeting that 'we are evaluating strategic options, but no final decision has been taken'. UBS analyst Daniel Brennan published a note saying 'the theoretical merger value could reach USD 8 billion; Curium's filing infrastructure would create additional value'.

If the transaction proceeds, market-concentration analyses by the FTC and the European Commission are expected to be completed by Q3 2026. Lantheus shares climbed from USD 92.40 to USD 104.20 at Tuesday's close, lifting market capitalisation to USD 7.1 billion. Accelerating sector consolidation will also affect other smaller players in the nuclear medicine market. Investment decisions are not personal financial advice.

M&AEarningsLNTHSouth AmericaInvesting.com Americas
This article is an AI-curated summary of the original story published by Investing.com Americas. The illustration is a stock photo by Pixabay from Pexels and is not from the original story.

More from South America